Clinical Research Organization News | CenterWatch News Online

CROs/Service Providers

Prev 10 31 32 33 34 35 36 37 38 39 40 Next 10

Unilife inks development and supply agreement

Tuesday, November 29, 2011 12:08 PM

Unilife has signed a clinical development and supply agreement with a global pharmaceutical company for a novel device for targeted organ delivery. The proprietary Unilife device is intended to be used in a drug clinical trial that is scheduled to commence in early 2012.

More... »

UCB inks strategic partnerships with Parexel, PRA

Monday, November 28, 2011 08:00 AM

The sponsor-CRO strategic partnerships just keep coming.

More... »

RaySearch signs South Korean distribution agreement with OTS

Wednesday, November 23, 2011 11:04 AM

RaySearch Laboratories has entered into an exclusive distribution agreement with the South Korean distributor Oncology Total Solution, based in Seoul. The agreement means that OTS will be fully responsible for marketing, sales and service for RaySearch’s proprietary treatment planning system RayStation on the South Korean market.

More... »

Ferring Pharmaceuticals to open operations center in New Jersey

Tuesday, November 22, 2011 02:07 PM

Switzerland-based Ferring Pharmaceuticals has purchased a 25-acre site in Parsippany, N.J. The new facility will house a state-of-the art, expanded U.S. Operations Center. The expansion is expected to generate jobs in the New Jersey area.

More... »

PAREXEL advances early phase research technology

Tuesday, November 22, 2011 11:55 AM

PAREXEL International has enhanced its central nervous system (CNS)
capabilities for clinical development through the implementation of
functional magnetic resonance imaging (fMRI) technology in its Early Phase
units. This advanced imaging scanning measures hemodynamic response, or
change in blood flow, related to neural activity in the brain or spinal
cord. Through this approach, PAREXEL is able to provide sponsors with
improved testing paradigms for cognitive biomarkers and better understand
the impact of compounds earlier in disease progression.

More... »

Tasly Pharmaceuticals selects ICON for phase III T89 trial

Monday, November 21, 2011 04:52 PM

ICON has been selected by Tasly Pharmaceuticals for the company’s global phase III T89 trial. T89, also known as Dantonic pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States. Dantonic pill is a botanical product for the treatment of chronic stable angina pectoris due to coronary heart disease. It is a modernized version of a traditional Chinese herbal medicine and was approved by the State Food and Drug Administration (SFDA) of China in 1993. Since then, more than 2 billion doses have been used by over 10 million patients.

More... »

Coviden to acquire BARRX Medical for $325 million

Monday, November 21, 2011 09:17 AM

BARRX Medical, a developer of minimally invasive medical devices, has signed a definitive agreement to be acquired by Covidien. Covidien is a global provider of healthcare products and a worldwide leader in advanced energy-based devices.

More... »

Redtree People, ICR launch learning service

Friday, November 18, 2011 12:36 PM

Redtree People and the Institute of Clinical Research (ICR) are to provide tailored training and education programs to the growing community of independent freelance clinical research professionals worldwide.

More... »

Survey: ICON Medical Imaging rated top provider

Thursday, November 17, 2011 01:14 PM

Dublin-based ICON has reported that its Medical Imaging division was rated as the top provider of imaging services according to an industry survey conducted by Blue Pyramid Consulting, an affiliate of the Avoca Group.

More... »

UCB enters strategic partnerships with Parexel and PRA

Thursday, November 17, 2011 10:33 AM

Brussels, Belgium-based UCB has entered into strategic partnerships with Parexel and PRA to drive UCB’s operational clinical development activities. The agreements are effective for all of UCB’s new clinical study programs on a global basis.

More... »